Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
- Aaron S. Mansfield, MD
- Roy S. Herbst, MD, PhD
- Gilberto de Castro, Jr., MD, PhD
- Rina Hui, MB, BS, PhD
- Nir Peled, MD, PhD
- Dong-Wan Kim, MD
- Silvia Novello, MD, PhD
- Miyako Satouchi, MD
- Yi-Long Wu, MD
- Edward B. Garon, MD
- Martin Reck, MD, PhD
- Andrew G. Robinson, MD
- Ayman Samkari, MD
- Bilal Piperdi, MD
- Victoria Ebiana, MD
- Jianxin Lin, MS
- Tony S.K. Mok, MD
DOIAbstract
Introduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive non–small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the efficacy of pembrolizumab versus chemotherapy. Methods: We pooled data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced or metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894). Patients received pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 wk or 10 mg/kg every 2 wk); chemotherapy was a comparator in all studies except KEYNOTE-001. All studies included pat...
Add to ORKG